

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 01 2001



On re the application of: Man Sung Co et al.

Serial No.: 09/627,896

Filed: July 27, 2000

For: *HUMANIZED IMMUNOGLOBULIN REACTIVE  
WITH B7-2 AND METHODS OF TREATMENT  
THEREWITH*

Attorney Docket No.: GNN-5315DV1

Group Art Unit: 1646 TECH CENTER 1600/2900

Examiner:

Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 22, 2001  
Date of Signature and of Mail Deposit

By:

Megan E. Williams  
Megan E. Williams, Esq.  
Registration No. 43,270  
Attorney for Applicants


INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a Divisional Application of U.S. Serial No. 09/249,011, filed February 12, 1999 (Atty. Docket No. GNN-5315). References B1 and B3-B9 listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 C.F.R. §1.98(d), copies of these references are not enclosed herewith, but will be provided


upon request. Reference B2 has not been previously cited by or submitted to the Office and is enclosed.



This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Megan E. Williams, Esq.  
Registration No. 43,270  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: May 22, 2001

AEM/MEW/JKR/alf

RECEIVED

JUN 01 2001

Sheet 1 of 1

APPLICANT FACSIMILE OF FORM PTO-1449  
REV 7-80U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

GNN-5315DV1

TECH

SERIAL NO

CENTER 1600/2900  
09/627,898

APPLICANT

Man Sung Co et al.

FILING DATE

July 27, 2000

GROUP

1646

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B1	6,084,067	07/00	Freeman et al.	530	350

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
B2	WO 95/34320	12/95	PCT		
B3	WO 96/14865	05/96	PCT		

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B4	Alegre, M-L. et al., Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors," <i>Digestive Diseases and Sciences</i> , 40(1):58-64 (1995)
B5	Bree, A.G. et al., "Humanized anti-B7-1 and anti-B7-2 antibodies prevent antigen specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps virus vaccine," <i>Blood</i> , 94(10) Suppl. 1 part 1, p. 439a (1999)
B6	Hathcock, K.S. et al., "Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses," <i>Advances in Immunology</i> , 62:131-166 (1996)
B7	Lenschow, D.J. et al., "Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse," <i>J. Exp. Med.</i> , 181:1145-1155 (1995)
B8	Lenschow, D.J. et al., "Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies," <i>Transplantation</i> , 60:1171-1178 (1995)
B9	Wettendorff, M. et al., "Generation of humanized Fab fragments of B7-24 mAb, an antibody with potential use in the prevention of graft rejection and development of graft-versus-host disease," <i>Med. Fac. Landbouwkundige en toegepaste biologische</i> , 60:2057-2063 (1995)

Examiner

Date Considered

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LAHIVE  
&  
COCKFIELD

LLP

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahcoc.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
NICHOLAS P. TRIANO, III  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN

SEAN D. DETWEILER  
CYNTHIA L. KANIK, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICH A. NAND  
MICHAEL PHILLIPPS \*

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
PETER C. LAURO \*

PATENT AGENTS  
PETER S. STECHER

RECEIVED  
# 1646  
TECHNICAL SPECIALISTS  
MAY 29 2001  
TECH CENTER 1600/2900  
JUN 1 2001  
PETER W. DINI, Ph.D.  
EDITH DON LEE  
LISA M. DIRCOCO  
JENNIFER K. ROSENFIELD  
JUDITH STONE-HULSLANDER, Ph.D.  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
ASHITA DASHI, Ph.D.  
JACOB G. WEINTRAUB

\* Admitted in NY only  
\*\* Passed the Patent Bar Examination

May 22, 2001

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Divisional Patent Application Serial No.: 09/627,896  
Title: *HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2  
AND METHODS OF TREATMENT THEREWITH*  
Inventor: Man Sung Co et al.  
Filed: July 27, 2000  
Our Ref. No.: GNN-5315DV1

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. PTO Form 1449;
3. A copy of one reference (B2) cited in PTO Form 1449; and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

May 22, 2001  
Date

Megan E. Williams, Esq., Registration No. 43,270

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Megan E. Williams, Esq.  
Registration No. 43,270  
Attorney for Applicants